Assembly Biosciences Inc (NASDAQ:ASMB) has been given a consensus rating of “Buy” by the six brokerages that are presently covering the firm, Marketbeat Ratings reports. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $42.50.
Several research firms recently weighed in on ASMB. BidaskClub downgraded Assembly Biosciences from a “buy” rating to a “hold” rating in a report on Saturday, January 6th. Zacks Investment Research raised Assembly Biosciences from a “hold” rating to a “buy” rating and set a $37.00 price objective on the stock in a report on Wednesday, November 15th. ValuEngine raised Assembly Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, February 3rd. Jefferies Group began coverage on Assembly Biosciences in a report on Wednesday, November 8th. They set a “buy” rating and a $50.00 price objective on the stock. Finally, B. Riley began coverage on Assembly Biosciences in a report on Friday, January 5th. They set a “neutral” rating and a $35.00 price objective on the stock.
Shares of Assembly Biosciences (ASMB) traded up $0.91 on Friday, hitting $57.50. The stock had a trading volume of 139,000 shares, compared to its average volume of 154,013. Assembly Biosciences has a one year low of $18.60 and a one year high of $58.68. The company has a market cap of $1,139.20, a price-to-earnings ratio of -19.36 and a beta of 0.77.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. MetLife Investment Advisors LLC acquired a new stake in shares of Assembly Biosciences during the 4th quarter valued at $326,000. Endurant Capital Management LP acquired a new position in Assembly Biosciences during the 4th quarter worth about $430,000. Millennium Management LLC lifted its holdings in Assembly Biosciences by 30.4% during the 4th quarter. Millennium Management LLC now owns 133,666 shares of the biopharmaceutical company’s stock worth $6,048,000 after buying an additional 31,195 shares during the period. TIAA CREF Investment Management LLC lifted its holdings in Assembly Biosciences by 46.8% during the 4th quarter. TIAA CREF Investment Management LLC now owns 72,331 shares of the biopharmaceutical company’s stock worth $3,273,000 after buying an additional 23,064 shares during the period. Finally, Teachers Advisors LLC lifted its holdings in Assembly Biosciences by 16.1% during the 4th quarter. Teachers Advisors LLC now owns 28,964 shares of the biopharmaceutical company’s stock worth $1,311,000 after buying an additional 4,025 shares during the period. 66.34% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION NOTICE: “Brokerages Set Assembly Biosciences Inc (ASMB) Price Target at $42.50” was published by Ticker Report and is the property of of Ticker Report. If you are accessing this report on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this report can be accessed at https://www.tickerreport.com/banking-finance/3226360/brokerages-set-assembly-biosciences-inc-asmb-price-target-at-42-50.html.
Assembly Biosciences Company Profile
Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.